Skip to main content
OpenTrials

Clinical trial condition

Unresectable Thyroid Gland Carcinoma

Explore clinical trials studying Unresectable Thyroid Gland Carcinoma. Study availability and eligibility vary by location and protocol.

7 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Unresectable Thyroid Gland Carcinoma trial results

Recruiting

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

NCT05668962

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +17 more
Locations
  • MedStar Washington Hospital Center Washington D.C., District of Columbia, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • University of Michigan Ann Arbor, Michigan, United States
View Trial Details
Completed

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

NCT02973997

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +38 more
Locations
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Torrance, California, United States
  • University of Colorado Hospital Aurora, Colorado, United States
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
View Trial Details
Completed

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

NCT00381641

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +37 more
Locations
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Decatur Memorial Hospital Decatur, Illinois, United States
  • NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois, United States
  • Ingalls Memorial Hospital Harvey, Illinois, United States
View all 17 locations
View Trial Details
Completed

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

NCT01208051

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +17 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California Davis Comprehensive Cancer Center P2C Sacramento, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View all 33 locations
View Trial Details

Related conditions